CLGN
CollPlant
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
RSI Overbought
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLGN
Collplant Biotechnologies Ltd.
A regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics
Biological Technology
11/09/1981
01/31/2018
NASDAQ Stock Exchange
57
12-31
Common stock
4 Oppenheimer, Weizmann Science Park, Rehovot 7670104, Israel
--
CollPlant Biotechnologies Ltd., was incorporated in Israel as a private limited company on November 9, 1981. The company is a regenerative and cosmetic medical company focusing on 3-D bioprinting and medical cosmetology of tissues and organs. The company's products are based on the patented plant genetic engineering technology produced by rhCollagen. The company's products are targeted for indications in a variety of fields, including tissue repair, aesthetics and organ manufacturing. The company's partners include Abbvie, STEMCELL, Tel Aviv University, Sheba Medical Center, ARMI and ReMDO, among others.
Company Financials
EPS
CLGN has released its 2025 Q1 earnings. EPS was reported at 0.1, versus the expected -0.37, beating expectations. The chart below visualizes how CLGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CLGN has released its 2025 Q1 earnings report, with revenue of 2.06M, reflecting a YoY change of 1996.94%, and net profit of -1.45M, showing a YoY change of 65.39%. The Sankey diagram below clearly presents CLGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
